Nanodrug Delivery Systems in Antitumor Immunotherapy

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Drug Delivery

Background:

• Cancer poses a significant global health threat with a rapidly increasing burden.
• Cancer immunotherapy is a crucial treatment modality, offering high efficiency and preventing metastasis.
• Clinical immunotherapy faces challenges including low response rates and immune-related adverse reactions.

Purpose of the Study:

• To review the integration of nanodrug delivery systems with various cancer immunotherapy strategies.
• To explore how nanotechnology can overcome current limitations in cancer immunotherapy.
• To discuss the role of nanomaterials in enhancing therapeutic outcomes and reducing toxicity.

Main Methods:

• Systematic review of research combining nanodrug delivery systems with immunotherapy.
• Categorization of applications into cytokine therapy, immune checkpoint blockade, tumor vaccines, and adoptive cell therapy.
• Detailed analysis of nanomaterial selection and their functional roles in nanodrug delivery systems.

Main Results:

• Nanodrug delivery systems significantly improve in vivo cytokine delivery for enhanced immunotherapy.
• Nanocarriers provide platforms for combining immune checkpoint blockade with other cancer treatments.
• Delivery of antigens and adjuvants via nanodrug systems boosts the efficacy of tumor vaccines.
• Nanotechnology improves treatment efficiency and reduces toxicity in adoptive cell therapy.

Conclusions:

• Nanodrug delivery systems represent a promising approach to advance cancer immunotherapy.
• The strategic use of nanomaterials can enhance immune responses and mitigate adverse effects.
• Further research into challenges and future prospects is essential for clinical translation.